Michael Mullan

Mullan was trained as a physician in England receiving his medical degree from the Royal Free Hospital, London University. As a physician, he won a clinical research fellowship in the UK and subsequently gained a PhD in molecular genetics, also from London University. In the UK and US he specialized in the diagnosis and treatment of Alzheimer's disease. He has co-authored over 200 papers on Alzheimer's disease and related disorders—on many of which he served as senior author. He has held positions as Professorial Chair and positions as professor of psychiatry, Neurology, and Pathology. He cofounded the Roskamp Institute, a not-for-profit, stand-alone biomedical research Institute and was its Director and CEO. Mullan was the CEO and chairman of Rock Creek Pharmaceuticals. Mullan is the CEO of Archer Pharmaceuticals, a for-profit spin-off of the Roskamp Institute. His work has focused on the development of new treatments for inflammatory disorders, particularly of the brain, with the ultimate goal of "reducing the burden of human suffering" associated with these diseases. Provided by Wikipedia
1
by U. Joshi, Andrew Pearson, James E. Evans, Heather Langlois, Nicole Saltiel, Joseph Ojo, N. Klimas, Kimberly Sullivan, Andrew P. Keegan, S. Oberlin, Teresa Darcey, Adam Cseresznye, Balaram Raya, Daniel Paris, B. Hammock, Natalia Vasylieva, S. Hongsibsong, Lawrence J. Stern, F. Crawford, Michael Mullan, L. Abdullah
Published 2019
Get full textPublished 2019
Get full text
Journal